protexam tests
Precision medicine for your patients
Personalized medicine in the clinic
We offer help for the individual diagnosis of diseases in your patients
Here we will introduce you to our tests registered as in-vitro diagnostics (IVD):
Chronic kidney disease
- Differential diagnosis -
The first changes in the kidney can be detected early with the protexam KDD test can be detected. With appropriate therapy, chronic kidney disease can be avoided.
If the test is positive, a distinction can also be made between the 7 most common chronic kidney diseases (diabetic nephropathy/nephrosclerosis, focal segmental glomerulosclerosis, IgA nephropathy, minimal change glomerulonephritis, ANCA-associated vasculitis, lupus nephritis, membranous nephropathy). This means that tissue examination (biopsy) of the kidney, an invasive procedure, can be avoided.
In some cases, a kidney biopsy is too dangerous: for example, if there is an increased tendency to bleed, severe high blood pressure or if only one kidney is left. The risk of a biopsy also increases if the patient is very overweight.
Referenzen:
- Good DM, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010, 9(11):2424-37.
- Siwy J, et al. Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. Nephrol Dial Transplant. 2017, 32(12):2079-2089.
Cholangiocarcinoma
One primary sclerosing cholangitis (PSC) can vhave various causes, such as blockage or narrowing of the bile ducts, but also tumors. To determine the cause, an endoscopic retrograde cholangiopancreatography (ERCP) is usually carried out, in which a special endoscope is pushed through the stomach into the bile ducts. As part of this UBile is also taken for examination.
With the
protexam BPA-CC test
The invasive ERCP can be supplemented with bile. The test also enables a more precise diagnosis in cases where there is an unclear suspicion of a bile duct tumor.
The protexam UPA-CC Test from urine is particularly suitable for the close, non-invasive monitoring of patients with inflammation of the bile ducts. Only if a tumor of the bile ducts is discovered at an early stage can life-saving surgical treatment be carried out. Removal possible.
With the
protexam combination test BPA/UPA-CC
Cholangiocarcinoma can be diagnosed with even greater precision using bile and urine.
Referenzen:
- Voigtländer T, et al. A combined bile and urine proteomic test for cholangiocarcinoma diagnosis in patients with biliary strictures of unknown origin. United European Gastroenterol J. 2017, 5(5):668-676.
Graft-versus-Host Disease (GvHD)
Blood stem cells are usually transplanted to treat leukemia. This can trigger a serious complication, an immunological response in the recipient's body, known as graft-versus-host disease (GvHD). About a third to a half of patients develop acute GvHD.
With the protexam UPA-GvHD test As an early warning system, GvHD can be detected 10 to 14 days before the first clinical symptoms appear. Early detection enables timely initiation of therapy and reliable monitoring of the measures taken.
Referenzen:
- Weissinger EM, et al. Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation. Leukemia. 2014, 28(4):842-52.